To the Editor: The study of prevention of poststroke depression by Dr Robinson and colleagues1 showed modest clinical effects of the SSRI escitalopram given over 12 months compared with placebo and problem-solving therapy. However, comparing the design of this study and its positive results with another poststroke depression study of the same group with negative results2 raises important questions.
Dettling M, Opgen-Rhein C, Anghelescu I. Escitalopram, Problem-Solving Therapy, and Poststroke Depression. JAMA. 2008;300(15):1757–1759. doi:10.1001/jama.300.15.1757-b
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: